PL369954A1 - Formulacje zawierające wirus ospy i proces otrzymywania stabilnych kompozycji zawierających wirus ospy - Google Patents

Formulacje zawierające wirus ospy i proces otrzymywania stabilnych kompozycji zawierających wirus ospy

Info

Publication number
PL369954A1
PL369954A1 PL02369954A PL36995402A PL369954A1 PL 369954 A1 PL369954 A1 PL 369954A1 PL 02369954 A PL02369954 A PL 02369954A PL 36995402 A PL36995402 A PL 36995402A PL 369954 A1 PL369954 A1 PL 369954A1
Authority
PL
Poland
Prior art keywords
poxvirus containing
poxvirus
freeze
preparing stable
dried
Prior art date
Application number
PL02369954A
Other languages
English (en)
Other versions
PL213326B1 (pl
Inventor
Paul Howley
Karl Heller
Ingmar Räthe
Original Assignee
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL369954(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Publication of PL369954A1 publication Critical patent/PL369954A1/pl
Publication of PL213326B1 publication Critical patent/PL213326B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL369954A 2001-12-10 2002-11-28 Formulacja zawierajaca wirus ospy, sposób jej otrzymywania i zastosowanie PL213326B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10

Publications (2)

Publication Number Publication Date
PL369954A1 true PL369954A1 (pl) 2005-05-02
PL213326B1 PL213326B1 (pl) 2013-02-28

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369954A PL213326B1 (pl) 2001-12-10 2002-11-28 Formulacja zawierajaca wirus ospy, sposób jej otrzymywania i zastosowanie

Country Status (21)

Country Link
US (1) US7094412B2 (pl)
EP (1) EP1418942B1 (pl)
JP (1) JP4439263B2 (pl)
KR (1) KR20040074067A (pl)
CN (1) CN1296096C (pl)
AT (1) ATE300954T1 (pl)
AU (1) AU2002361962A1 (pl)
BR (1) BR0214822A (pl)
CA (1) CA2467365C (pl)
DE (1) DE60205388T2 (pl)
DK (1) DK1418942T3 (pl)
EA (1) EA006880B1 (pl)
ES (1) ES2247414T3 (pl)
HU (1) HUP0402179A3 (pl)
IL (2) IL161590A0 (pl)
MX (1) MXPA04005577A (pl)
NO (1) NO20042958L (pl)
NZ (1) NZ533302A (pl)
PL (1) PL213326B1 (pl)
UA (1) UA78738C2 (pl)
WO (1) WO2003053463A2 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
EP2148923B1 (en) * 2007-05-18 2012-08-22 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
EP2571521A1 (en) 2010-05-21 2013-03-27 Ah Usa 42 Llc Parapoxvirus vectors containing rabies virus antigen
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
WO2012011045A1 (en) 2010-07-20 2012-01-26 Pfizer Inc. Parapoxvirus vectors
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EP3116541B1 (en) 2014-03-12 2019-11-27 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
US11052147B2 (en) * 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR CANCER THERAPY
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
JP7810554B2 (ja) 2019-03-01 2026-02-03 アケロイス バイオファーマ， インコーポレイテッド 抗原特異的免疫細胞におけるｃｄ１６０機能をモジュレートする方法およびその使用
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
US12029787B2 (en) 2020-07-01 2024-07-09 University Of Connecticut Method for generating recombinant poxviruses
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20250387463A1 (en) 2022-06-29 2025-12-25 Bavarian Nordic A/S Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen
CN119604618A (zh) 2022-06-29 2025-03-11 巴法里安诺迪克有限公司 爱泼斯坦-巴尔病毒疫苗
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
JP2026502453A (ja) 2023-01-12 2026-01-23 バヴァリアン・ノルディック・アクティーゼルスカブ がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ）
EP4677074A1 (en) 2023-03-10 2026-01-14 Bavarian Nordic A/S Production of poxviruses from quail cell cultures
EP4677076A1 (en) 2023-03-10 2026-01-14 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (pl)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (pl) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
EP0951555A2 (en) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
DE60205388D1 (de) 2005-09-08
CA2467365A1 (en) 2003-07-03
JP4439263B2 (ja) 2010-03-24
EA200400796A1 (ru) 2004-12-30
ES2247414T3 (es) 2006-03-01
EP1418942A2 (en) 2004-05-19
AU2002361962A1 (en) 2003-07-09
WO2003053463A2 (en) 2003-07-03
JP2005513109A (ja) 2005-05-12
US7094412B2 (en) 2006-08-22
WO2003053463A3 (en) 2004-03-04
CN1296096C (zh) 2007-01-24
NO20042958L (no) 2004-07-09
DK1418942T3 (da) 2005-11-28
DE60205388T2 (de) 2006-03-30
CA2467365C (en) 2012-11-20
MXPA04005577A (es) 2005-04-19
PL213326B1 (pl) 2013-02-28
US20050019349A1 (en) 2005-01-27
CN1602205A (zh) 2005-03-30
EP1418942B1 (en) 2005-08-03
HUP0402179A3 (en) 2012-09-28
HUP0402179A2 (hu) 2005-01-28
BR0214822A (pt) 2004-12-14
IL161590A0 (en) 2004-09-27
KR20040074067A (ko) 2004-08-21
EA006880B1 (ru) 2006-04-28
IL161590A (en) 2009-06-15
NZ533302A (en) 2005-11-25
UA78738C2 (en) 2007-04-25
ATE300954T1 (de) 2005-08-15
HK1071295A1 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
IL161590A0 (en) Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
IL159724A0 (en) A nitrogen oxide generating composition for treatment of nail infections
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
NZ596367A (en) Lyophilized therapeutic peptibody formulations
WO2001070132A3 (en) Injectable and swellable microspheres for dermal augmentation
EP1570840A3 (en) Topical composition comprising n-acetylaldosamines or n-acetylamino acids
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
MY128368A (en) Method for producing quickly decomposable solid pharmaceutical preparations
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
WO2003016544A1 (fr) Procede d'elaboration d'acide 1,4-dihydroxy-2-naphtoique
WO2004080415A3 (en) Gel composition and method for treatment of vaginal infections
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
NZ598702A (en) A micro-rna family that modulates fibrosis and uses thereof
SI1684719T1 (sl) Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
WO2002009679A3 (en) Use of 13-cis retinoic acid for the treatment of emphysema
EP1495763A4 (en) THERAPEUTIC CREAM AGAINST DERMATITIS
CO5221126A1 (es) Metodo parta la preparacion de ingredientes alimenticios proteinicos de soya e ingredientes asi obtenidos
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
CN1331968A (zh) 一种中药牙膏
BR0008739A (pt) Composições de liberação controlada debeta-histina
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
WO2024261351A3 (en) Immunologically active saponin fractions and adjuvant formulations
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
CN106619173A (zh) 一种头发定型剂及其制备方法